norfloxacin has been researched along with Mycoses in 11 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Mycoses: Diseases caused by FUNGI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of a combination regimen using norfloxacin (NFLX) and amphotericin B (AMPH-B) for prevention of infections in patients with acute leukemia being treated by remission-induction chemotherapy in a randomized, controlled trial was studied." | 9.07 | Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. ( Dan, K; Nomura, T; Yamada, T, 1993) |
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 9.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| "We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days)." | 9.06 | Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1987) |
| "The effect of a combination regimen using norfloxacin (NFLX) and amphotericin B (AMPH-B) for prevention of infections in patients with acute leukemia being treated by remission-induction chemotherapy in a randomized, controlled trial was studied." | 5.07 | Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. ( Dan, K; Nomura, T; Yamada, T, 1993) |
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 5.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| "We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days)." | 5.06 | Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1987) |
| "Selective antimicrobial decontamination with norfloxacin was compared with vancomycin/polymyxin for prophylaxis of bacterial infections in granulocytopenic patients." | 3.67 | Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. ( Champlin, RE; Gale, RP; Ho, WG; Nakao, SL; Winston, DJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Makawana, JA | 1 |
| Mungra, DC | 1 |
| Patel, MP | 1 |
| Patel, RG | 1 |
| Shelke, SN | 1 |
| Mhaske, GR | 1 |
| Bonifácio, VD | 1 |
| Gawande, MB | 1 |
| Yin, BT | 1 |
| Yan, CY | 1 |
| Peng, XM | 2 |
| Zhang, SL | 1 |
| Rasheed, S | 1 |
| Geng, RX | 2 |
| Zhou, CH | 2 |
| Karad, SC | 1 |
| Purohit, VB | 1 |
| Thakor, P | 1 |
| Thakkar, VR | 1 |
| Raval, DK | 1 |
| Jeyakkumar, P | 1 |
| Liu, HB | 1 |
| Gopala, L | 1 |
| Cheng, Y | 1 |
| Yamada, T | 2 |
| Dan, K | 2 |
| Nomura, T | 2 |
| Zwaveling, JH | 1 |
| Maring, JK | 1 |
| Klompmaker, IJ | 1 |
| Haagsma, EB | 1 |
| Bottema, JT | 1 |
| Laseur, M | 1 |
| Winter, HL | 1 |
| van Enckevort, PJ | 1 |
| TenVergert, EM | 1 |
| Metselaar, HJ | 1 |
| Bruining, HA | 1 |
| Slooff, MJ | 1 |
| Ogata, K | 1 |
| Tanabe, Y | 1 |
| Iwakiri, K | 1 |
| Ito, T | 1 |
| Winston, DJ | 2 |
| Ho, WG | 2 |
| Nakao, SL | 1 |
| Gale, RP | 1 |
| Champlin, RE | 2 |
| Karp, J | 1 |
| Bartlett, J | 1 |
| Finley, RS | 1 |
| Joshi, JH | 1 |
| Talbot, G | 1 |
| Levitt, L | 1 |
| Deresinski, S | 1 |
| Karp, JE | 1 |
| Merz, WG | 1 |
| Hendricksen, C | 1 |
| Laughon, B | 1 |
| Redden, T | 1 |
| Bamberger, BJ | 1 |
| Bartlett, JG | 1 |
| Saral, R | 1 |
| Burke, PJ | 1 |
4 trials available for norfloxacin and Mycoses
| Article | Year |
|---|---|
Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B.
Topics: Administration, Oral; Adult; Amphotericin B; Antineoplastic Agents; Bacterial Infections; Drug Combi | 1993 |
Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Decontaminati | 2002 |
Norfloxacin for prevention of bacterial infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Drug Combinations; Drug Therapy, Com | 1987 |
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents | 1987 |
7 other studies available for norfloxacin and Mycoses
| Article | Year |
|---|---|
Microwave assisted synthesis and antimicrobial evaluation of new fused pyran derivatives bearing 2-morpholinoquinoline nucleus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Candida albicans; Fungi; Gram-Negative Bacte | 2011 |
Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; Green Chemistry | 2012 |
Synthesis and biological evaluation of α-triazolyl chalcones as a new type of potential antimicrobial agents and their interaction with calf thymus DNA and human serum albumin.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Cattle; Chalcones; DNA; Fungi; Human | 2014 |
Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
Topics: Anti-Infective Agents; Antimalarials; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; | 2016 |
Novel benzimidazolyl tetrahydroprotoberberines: Design, synthesis, antimicrobial evaluation and multi-targeting exploration.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Benzimidazoles; Berberine Alkaloids; | 2017 |
Two cases of disseminated Trichosporon beigelii infection treated with combination antifungal therapy.
Topics: Adult; Amphotericin B; Drug Combinations; Flucytosine; Humans; Leukemia, Myeloid, Acute; Lymphoma, N | 1990 |
Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Drug Evaluation; Drug Tolerance; Fem | 1986 |